The University of Kentucky is exploring the potential of an investigational dementia drug in easing alcohol withdrawal symptoms. The medication, known as MW150, targets a brain inflammation pathway linked to addiction and relapse, called p38α MAPK. While it is primarily designed for treating mild to moderate Alzheimer’s disease, MW150 might offer benefits for alcohol use disorder patients.
Research Findings
Research from the University of Kentucky’s Sanders-Brown Center on Aging, led by Linda Van Eldik, has shown that MW150 can reduce inflammatory markers during alcohol withdrawal in laboratory and animal tests. Caleb Bailey, Ph.D., a co-author of the study, emphasized the drug’s potential for mitigating inflammation associated with withdrawal symptoms. He noted that the high relapse rates during withdrawal make alcohol use disorder challenging to treat.
Potential Implications
Bailey mentioned that further research with animal models is needed to confirm MW150’s anti-inflammatory effects in the context of alcohol use disorder. Given that MW150 and a similar drug, Neflamapimod, are under investigation for treating dementia and other neurodegenerative diseases, there is optimism that these drugs could be repurposed for alcohol-related conditions if future studies are promising.
“If follow-up experiments reveal similar anti-inflammatory effects of MW150 in animal models of alcohol use disorder, it would provide a strong rationale for development as a treatment,” Dr. Bailey told Fox News Digital.
Caveats and Considerations
However, some limitations exist. The initial research was conducted in cell culture and animal models, which do not fully replicate the complexities of an entire organism or brain. Comprehensive studies with living animals are necessary to better understand how MW150 affects systemic health and alcohol consumption.
Dr. Amy Swift, a notable authority on alcohol use disorder, explained that traditional detoxification addresses the immediate complications of alcohol withdrawal but not the disorder itself. She highlighted the importance of exploring supportive medications that target overall brain health to enhance detoxification outcomes.
Expert Views
Swift and Bailey both emphasized the need for reducing neuroinflammation to improve patient engagement in treatment and alter their long-term relationship with alcohol. Swift stated, “It’s worthwhile to investigate whether reducing neuroinflammation could improve a patient’s ability to engage in treatment earlier in recovery.”
Bailey further noted that, from a health perspective, minimizing alcohol consumption remains the best strategy due to the lack of effective pharmacological treatments for the damage caused by chronic consumption.
As MW150 continues to undergo research for dementia patients, understanding its interaction with alcohol will be crucial for optimizing patient outcomes.
Leave a Reply